Pleural Mesothelioma

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations

Primary Outcome Measures Occurrence of Dose Limiting Toxicity [ Time Frame: over the first 21 days of dosing ] Incidence of Adverse and Serious Adverse Events Occurrence of General Toxicity [ Time Frame: through study completion, an average of 30 months ] Incidence of Adverse and Serious Adverse Events, Discontinuations due to Adverse Events and general safety Evaluations[…]

Read More »

People with an Inherited Mutation on the BLM Gene Could Be More at Risk of Developing Mesothelioma

New research from the University of Hawaii is showing that the inherited mutation on the BLM gene can increase the chance of getting mesothelioma. The researchers sequenced the DNA of 155 mesothelioma patients. People without the BLM gene were more likely to develop mesothelioma, especially when exposed to carcinogenic asbestos[…]

Read More »

Cholesterol Drugs Called Statins Could Help Extend Mesothelioma Sufferers’ Lives

A group of drugs called statins used for controlling cholesterol are showing that they can help mesothelioma patients taking PD-1 inhibitors survive longer. Researchers in Italy and the Netherlands found this information in an international study of 250 patients. The patients studied either had pleural mesothelioma or non-small cell lung[…]

Read More »

The ONCOS-102 Vaccine is Still Showing Promising Results

The ONCOS-102 immunotherapy vaccine is still showing promising results. Information from November shows when patients take the treatment with chemotherapy, it helped patients survive a minimum of 18.2 months. The median overall survival was four months better in the experimental group compared to the control group. Targovax, the maker of[…]

Read More »

Mesothelioma Symptom Management Tool Links Doctors and Patients with a Smartphone

A study looking at a system that connects doctors and patients with a smartphone is showing that it could make the management of mesothelioma symptoms easier. Mesothelioma is a fast growing and aggressive cancer that has many different physical symptoms. Researchers in the United Kingdom are looking at a mesothelioma[…]

Read More »

The Herpes Virus is Being Tested as a Mesothelioma Treatment

An altered herpes virus is being tested in mesothelioma patients, and the results show that it can stabilize the growth of mesothelioma tumors. Half of the patients given the virus responded to the treatment, which is very promising. Thirteen patients were injected with a version of HSV (herpes causing virus)[…]

Read More »

Reducing UHRF1 Could Lengthen Mesothelioma Sufferers’ Lives

The protein UHRF1 could help people survive pleural mesothelioma. Research from the National Cancer Institute found this protein. The protein is encoded by the gene with the same name. Researchers in the study believe that it could cause the growth and spread of mesothelioma. The information needs to be confirmed[…]

Read More »

A New T-Cell Treatment is Being Tested on Mesothelioma Patients

A new clinical trial at the Memorial Sloan Kettering Cancer Center is recruiting patients for a pleural mesothelioma study. The treatment involves T-cell therapy and is a very promising treatment for mesothelioma sufferers. The reason the study is being done is ATA2271, which is known as CAR T-cell therapy, was[…]

Read More »

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

This study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an MSLN-targeted CAR-T cell treatment with an anti-PD1 component is being given to people.

Read More »

Opdivo and Yervoy Have Been Fully Approved for Treating Mesothelioma

A new treatment has been approved for mesothelioma by the Food and Drug Administration (FDA). The treatment uses a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), which are immunotherapy drugs created by Bristol-Myers Squibb. It is the first new drug combination approved for mesothelioma in 16 years. The most recent[…]

Read More »